Curocell Inc. (KOSDAQ:372320)

Curocell Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023
Cost of Revenue	16.33	10.49	14.19
Gross Profit	-16.33	-10.49	-14.19
Selling, General & Admin	4,628	4,632	3,821
Research & Development	32,736	31,864	27,191
Amortization of Goodwill & Intangibles	54.88	3.87	1.5
Other Operating Expenses	88.43	14.51	11.22
Operating Expenses	37,610	36,614	31,116
Operating Income	-37,627	-36,624	-31,130
Interest Expense	-3,687	-2,603	-2,431
Interest & Investment Income	453.91	938.26	617.54
Currency Exchange Gain (Loss)	-15.25	-24.34	-14.64
Other Non Operating Income (Expenses)	1,617	83.35	3,305
EBT Excluding Unusual Items	-39,258	-38,230	-29,652
Gain (Loss) on Sale of Assets	1.24	-8.18	-11.24
Pretax Income	-39,257	-38,238	-29,664
Income Tax Expense	1.1	1.1	-88.73
Net Income	-39,258	-38,239	-29,575
Net Income to Common	-39,258	-38,239	-29,575
Shares Outstanding (Basic)	14	14	12
Shares Outstanding (Diluted)	14	14	12
Shares Change (YoY)	3.98%	18.10%	-
EPS (Basic)	-2755.02	-2736.20	-2499.18
EPS (Diluted)	-2755.02	-2736.20	-2499.18
Free Cash Flow	-30,968	-28,863	-46,428
Free Cash Flow Per Share	-2173.29	-2065.28	-3923.32
EBITDA	-31,480	-30,289	-26,424
D&A For EBITDA	6,146	6,335	4,706
EBIT	-37,627	-36,624	-31,130
Advertising Expenses	-	43.48	45.38

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.